Precision Therapeutics in Non-Scarring Alopecia: A Systemic Genomic and Pathway-Based Framework for Targeted Interventions

This Mendelian randomization study found that specific dietary patterns, such as consuming antioxidant-rich foods like melon and tea, may have protective effects against hair loss, while processed carbohydrates, alcohol, and certain dairy products could increase the risk of androgenetic alopecia and alopecia areata.

This review highlights recent advancements in androgenetic alopecia treatment, focusing on the dysregulated signaling pathways involved in hair follicle regeneration and exploring innovative therapeutic strategies, including small molecule modulators and gene editing technologies, which show promise in preclinical models.

This review highlights that recent advancements in diagnostics and therapies, including AI-enhanced imaging, biomarker analysis, and novel treatments like low-dose oral minoxidil and JAK inhibitors, are improving the precision and customization of hair loss management.

This study found that QR678 Neo® significantly enhanced hair regrowth, density, and shaft diameter in males with advanced androgenetic alopecia undergoing hair transplant surgery, compared to a conventional method, making it a promising adjunct treatment option.

This study suggests that novel diagnostic, preventive, and treatment approaches for autoimmune diseases like alopecia areata may be developed by identifying hub genes, and highlights the usefulness of machine learning and bioinformatics in finding new disease biomarkers.

This case report describes a 28-year-old woman who developed alopecia areata following prolonged emotional stress, with improvement observed using Minoxidil and stress management, but relapse occurred after another stressful period.

This review discusses the prevalence, pathogenesis, and treatments of androgenic alopecia but reports no new research findings; the authors emphasize the need for further exploration of novel treatment options.

This review discusses genetic and pharmacogenetic insights, along with RNA interference technologies, for developing personalized therapies for androgenetic alopecia, yet presents no new clinical results.

This study explored the effectiveness of injectable treatments for androgenetic alopecia, finding that dutasteride and growth factor formulations achieved clinically significant results compared to controls like saline and topical minoxidil, within selected trials from 2000 to 2023.

This study found that oral administration of solubilized sturgeon oil in mice promoted hair growth and positively influenced the gut microbiome associated with hair growth promotion.

The study was retracted.

This review discusses the potential for surface-modified nanostructured lipid carriers to enhance hair regrowth by improving drug absorption and stability, focusing on their use with agents like minoxidil and finasteride for hair loss treatment.

This review discusses the increasing prevalence of alopecia in younger populations and outlines the need for better understanding its pathogenesis to develop effective treatments. It also examines current FDA-approved drugs and emerging small molecule compounds with potential anti-alopecia effects.

This study found that specific PITX2 gene variants are significantly associated with higher risk of androgenetic alopecia in males, highlighting important genetic and environmental interactions influencing its development.

This study found that 1,25-dihydroxyvitamin D3 promotes hair growth and regeneration in mice by prolonging the anagen phase and counteracting DHT's inhibitory effects, suggesting its potential therapeutic role for androgenetic alopecia.

This manuscript reviews the latest understanding of alopecia areata's pathogenesis, highlighting the roles of genetic, immunological, and environmental factors, with a focus on immune responses involving IFN-γ and cytotoxic CD8+ T-cells as key contributors to hair follicle inflammation and function disruption without follicle destruction.

This narrative review reports that well-selected plant extracts and their active compounds may improve hair health by promoting hair growth and preventing hair loss, potentially aiding in developing targeted therapies for alopecia.

This study used Mendelian randomization analysis to identify Scyllo-inositol and Alpha-ketoglutarate as potential protective factors and Heme and 2-palmitoylglycerophosphocholine as risk factors for androgenic alopecia, suggesting a causal link between these metabolites and the condition.

This study identified eight genetic markers associated with androgenetic alopecia, suggesting that these SNPs could influence individualized therapeutic responses and highlight the need for personalized treatment strategies.

This review outlines the functional anatomy, pathology, and molecular mechanisms of androgenetic alopecia, emphasizing the need for multi-omics approaches to better understand this condition's biology.

This study identified a reduced frequency of IL-10-producing regulatory B cells in alopecia areata patients, suggesting a protective role by these cells in disease development by regulating key immune mediators, such as IFN-γ and NKG2D+CD8+ T cells.

This review explores the link between androgenetic alopecia, advanced glycation end products, and RAGE, noting their potential role in exacerbating oxidative stress and inflammation related to hair follicle miniaturization.

This study found that androgenetic alopecia patients exhibited impaired arginine metabolism in balding hair follicles, suggesting that arginine supplementation may help preserve hair growth by counteracting mTOR signaling pathway disruption and offering potential as a treatment strategy.

This review suggests that the gut microbiome and metabolome may play a significant role in alopecia areata and emphasizes the potential of targeting these factors for improved prevention, diagnosis, and treatment strategies for this skin condition.

This study found that intradermal QR678 Neo® therapy improved scalp condition in men and women with seborrheic dermatitis unresponsive to standard treatments, reducing flaking and inflammation after eight sessions, with high patient satisfaction reported.

This review discusses the association between emotional stress-related neuropeptides and the pathogenesis of alopecia areata, reporting no new experimental findings.

This study highlights the genetic complexities in alopecia areata, emphasizing the role of microRNAs and their association with other immune-related diseases, which could inform targeted treatment strategies.

This study identified shared gene expression changes and immune cell infiltration patterns that may contribute to hair loss in alopecia areata and cutaneous lupus erythematosus, but also highlighted factors that might preserve hair in psoriasis patients.

This study analyzed gene expression data to identify key genes involved in severe forms of alopecia areata, discovering four immune monitoring genes (LGR5, SHISA2, HOXC13, S100A3) with potential for early diagnosis and better understanding of the disease's biological mechanisms.

This review discusses recent advances in understanding and treating alopecia areata, emphasizing the ongoing challenges and unmet needs in disease management; it reports no new clinical findings.

In this Mendelian randomization study, shortened leukocyte telomere length was associated with an increased risk of androgenetic alopecia, but no causal relationship was found with alopecia areata.

This review discusses the histological features and diagnostic challenges of alopecia areata and emphasizes the need for genetic research to develop future therapeutics; it reports no new clinical findings.

This study identified a long noncoding RNA, LOXL1-AS1, with potential diagnostic significance in androgenic alopecia, which may regulate TP53 expression by targeting hsa-miR-5193 within a ceRNA network.

This study found that people with alopecia areata have a higher likelihood of experiencing anxiety and depression, and a moderate negative impact on their quality of life compared to healthy individuals.

This review discusses the roles of prostaglandins in hair loss and highlights their potential as targets for new alopecia treatments, but reports no new clinical findings.

This article discusses the efficacy of different derma roller sizes compared to topical applications for administering QR678 Neo® in treating androgenetic alopecia, but provides no new clinical results.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review discusses the role of hair follicle stem cell metabolism, ageing, and microenvironment in hair growth disorders and compiles recent research on using stem cell-based regenerative medicine for treating alopecia, without reporting new clinical results.

This review explores regenerative treatment options for non-scarring alopecia, with a focus on the potential of mesenchymal stem cells for hair regrowth, but it reports no new clinical results.

This study found that overexpression of the lncRNA AC010789.1 in hair follicle stem cells may suppress androgen alopecia progression by modulating several molecular pathways, suggesting a potential new treatment strategy.

This study found that intradermal administration of QR678 Neo® significantly reduced hair fall and improved hair growth in patients with androgenetic alopecia and female pattern hair loss, with no side effects reported during long-term follow-up.

The book explains causes and treatments for common hair loss, its psychological effects, related health risks, and emphasizes early screening and lifestyle changes.

In this study of 20 female patients with Covid-19-induced persistent Telogen Effluvium, intra-dermal QR678 Neo® treatments led to significant reductions in hair fall and increases in hair growth and density, sustained even post-therapy.

The researchers reported that QR678 Neo® combined with intralesional steroids significantly improved hair regrowth and patient satisfaction in treating alopecia areata compared to steroids alone.

This review discusses the potential of miRNA-mediated hair growth treatments for androgenetic alopecia by targeting DKK1 to modulate the Wnt/β-catenin signaling pathway and reports no new clinical findings.

This meta-analysis reported that finasteride 1 mg/day significantly increased hair count in male androgenetic alopecia compared to placebo, but highlighted persistent sexual side effects and associated depression risk.

This review discusses the potential link between androgenetic alopecia and COVID-19 severity, examining the role of androgens and relevant treatments, but reports no new clinical results.

In this study, SFRP1 expression was found to be upregulated in hair follicles from men with androgenetic alopecia, with the transcription factor FOXC1 playing a significant role in its regulation.

MicroRNAs may help diagnose and treat hair loss disorders.

Combination therapy with QR 678 Neo and 5% Minoxidil is most effective for male hair loss.

This study found that both intradermal injection and derma roller techniques for QR678Neo® hair regrowth therapy improved androgenetic alopecia symptoms, with intradermal injections showing non-significantly better video-microscopic outcomes but more pain and erythema associated with derma rollers.

This review discusses the role of telomere length dynamics in hair follicle biology and reports no new clinical findings, emphasizing the need for further research in humans.

This study found that patients with androgenetic alopecia exhibit specific miRNA expression profiles, suggesting that abnormal miR-133b expression may inhibit the Wnt/β-catenin pathway and affect hair growth.

Finasteride may cause side effects; more research needed.

This review article summarizes the potential role of advanced medical therapies—using genes, cells, and/or tissue engineering—in treating various types of alopecia, by examining clinical research, basic studies, and ongoing trials.

In this study, miR-324-3p was found to promote differentiation and migration in cultured keratinocytes and is highlighted as a potential target for treating androgenic alopecia.

In this study, QR678® and QR678 Neo® injections significantly improved hair density and thickness in women with PCOS-related alopecia over eight sessions, with effects lasting over a year.

This study found that most chronic alopecia areata patients treated with azathioprine, methotrexate, or cyclosporine continued treatment for at least 12 months, often requiring concurrent low-dose prednisolone.

In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.

This review discusses the potential of stem cell-based therapies, particularly involving stem cell-derived conditioned medium and exosomes, for hair regeneration in nonscarring alopecia, but it reports no new clinical outcomes.

In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.

This review discusses potential biomarkers for alopecia and their significance, and while it highlights areas for future research, it reports no new clinical results.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study found that hair thickness and density increased after treatment with human follicle mesenchymal stem cells and platelet rich plasma, associated with enhanced Wnt signaling and platelet derived growth factors.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This review discusses how modern lifestyle factors affecting gut health may contribute to Alopecia Areata in genetically predisposed individuals, reporting no new results but suggesting the need for long-term interventions.

This study demonstrates that inhibiting SFRP1 with the antagonist WAY-316606 enhances hair growth in human scalp hair follicles ex vivo by facilitating Wnt signalling.

In this study, researchers administered eight sessions of intradermal injections containing growth factors into the scalp of 1000 patients, reporting a significant reduction in hair fall in 83% of participants and increased total hair count and shaft diameter, with promising tolerance and safety.

This study found that human umbilical cord blood mesenchymal stem cells promoted hair growth by advancing anagen onset and increasing hair follicle regeneration in an in vivo model.

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This study found that topical minoxidil 5% foam was effective in promoting hair growth in both the frontal and vertex scalp for men with androgenetic alopecia.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

Four genetic risk spots found for hair loss, with WNT signaling involved and a link to curly hair.

PGD2 stops hair growth and is higher in bald men with AGA.

This study found that androgens inhibit hair follicle stem cell differentiation by disrupting the Wnt signalling pathway in dermal papilla cells, but Wnt activation can restore differentiation.

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

A gene called APCDD1, which controls hair growth, is found to be faulty in a type of hair loss called hereditary hypotrichosis simplex.

This review discusses the potential role of oxidative stress in hair graying and age-related alopecia, emphasizing the need for new strategies to counteract these effects, but reports no new results.

EDA2R gene linked to hair loss.

In this study, researchers found that while the SNP rs6152 is strongly associated with androgenetic alopecia, the GGN triplet repeat is not, suggesting the causative variant is likely a non-coding one.

In this study, decreased expression of BMP2 and ephrin A3 and increased NT-4 gene expression were observed in dermal papilla cells from androgenic alopecia-affected skin, suggesting potential roles in hair growth regulation.

This study found that specific genetic markers near the androgen receptor gene are significantly more common in men with male pattern baldness, suggesting a genetic component in its development.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

This study found that dermal papilla cells from balding scalp hair follicles have significantly higher levels of androgen receptors than those from non-balding follicles, supporting their in vivo androgen response.